Parameter
| Biomarker | IL-6 | Full name | Interleukin-6 | Molecular Type | Proteins (cytokines) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognostic assessment, association with neurocognitive function |
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Blood and lymphoid tissue | Test Sample / Technology Platform | Serum（Luminex、ELISA） | ||
| Pathobiological Mechanisms | Reflects systemic inflammatory status, with high levels indicating a high risk of recurrence and associated with neurocognitive impairment in HL survivors. | ||||
| Clinical Availability Status | Clinical application/research phase: Pre-treatment high IL-6 and hs-CRP levels were associated with short RFS; hs-CRP ≥3 mg/L was correlated with poor attention and memory function. | ||||
| Notes and Dynamics | The association between IL-6-mediated pulmonary disease and visual-motor processing speed can serve as a target for intervention trials. | ||||